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Background: Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester
indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL)
hypertriglyceridemia. ANCHOR was a 12-week, phase 3 study that evaluated the efficacy and safety of IPE in
patients (N = 702) with residual high fasting TG levels (≥200 and <500 mg/dL) despite having optimized
low-density lipoprotein cholesterol (LDL-C) levels (≥40 and <100 mg/dL) on statin therapy. Among patients
randomized to IPE (4 g/day or 2 g/day) or placebo, 514 (73%) had diabetes mellitus.
Methods: A post hoc subgroup analysis of the ANCHOR study was conducted to assess the effects of IPE on
median placebo-adjusted percent change from baseline in efficacy end point parameters in 3 subgroups: total (all
subjects with diabetes—overall median baseline glycosylated hemoglobin A1c [A1c] = 6.8%), better-controlled
diabetes (below median baseline A1c), and less-controlled diabetes (above median baseline A1c).
Results: Baseline efficacy parameters were similar among all groups except high-sensitivity C-reactive protein
(hsCRP), which was higher in the total and less-controlled diabetes groups. Compared with placebo, IPE 4 g/day
significantly reduced TG, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol (VLDL-C),
lipoprotein-associated phospholipase A2, apolipoprotein B (Apo B), total cholesterol, high-density lipoprotein
cholesterol, VLDL-TG, oxidized LDL, and remnant-like particle cholesterol in all 3 diabetes groups, LDL-C in the total
diabetes group, and hsCRP in the total and less-controlled diabetes groups. Decreases in hsCRP and Apo B were
much greater in patients with less-controlled diabetes. There were no significant increases in fasting plasma
glucose, A1c, insulin, or homeostasis model assessment-estimated insulin resistance in any group.
Conclusion: IPE 4 g/day significantly improved lipid and lipid-related parameters without worsening glycemic
control in patients with diabetes and mixed dyslipidemia, with possibly greater effects among those with
less-controlled diabetes.
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The US Center for Disease Control and Prevention reports
that the crude age-adjusted prevalence of diagnosed dia-
betes mellitus has risen by >175% from 1980 to 2010 [1].
The risk for all forms of cardiovascular disease (CVD) is
considerably elevated in patients with diabetes mellitus,
and this is driven in part by the high prevalence of
dyslipidemia in this population [2]. Low-density lipoprotein
cholesterol (LDL-C) levels ≥100 mg/dL are found in ap-
proximately 64% of adults with diabetes mellitus-2, while
35% have fasting triglyceride (TG) levels ≥200 mg/dL [3].
Elevated TG levels in people with diabetes mellitus are
often associated with decreased high-density lipoprotein
cholesterol (HDL-C) and small, dense LDL particles [4].
Although reducing LDL-C with statins is the basis of
dyslipidemia treatment in patients with diabetes mellitus,
considerable residual CVD risk remains in statin-treated
patients [5,6]. Non–HDL-C is the secondary treatment
target if TG levels remain ≥200 and <500 mg/dL after
optimization of statin therapy [7,8]. Modifying other lipid,
lipoprotein, and inflammation-related risk factors beyond
LDL-C and non–HDL-C may provide additional ap-
proaches in addressing the residual CVD risk [5].
Omega-3 (OM-3) fatty acids have the potential to lower
CVD risk, as they have been shown to improve several car-
diovascular risk factors, particularly lowering TG levels
[4,9]. Currently approved OM-3 fatty acid formulations
contain either a combination of eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA), or EPA alone.
Icosapent ethyl (IPE; Vascepa® [formerly AMR101]; Amarin
Pharma Inc., Bedminster, NJ, USA) is a high-purity pre-
scription form of EPA ethyl ester approved by the US Food
and Drug Administration as an adjunct to diet to reduce
TG levels in adult patients with severe (≥500 mg/dL)
hypertriglyceridemia.
In the 12-week ANCHOR study of patients with
residual high TG levels (200–500 mg/dL) despite having
optimized LDL-C (40–100 mg/dL) while on statin
therapy, IPE 4 g/day was shown to significantly
reduce TG, LDL-C, non–HDL-C, very-low-density lipo-
protein cholesterol (VLDL-C), lipoprotein-associated
phospholipase A2 (Lp-PLA2), apolipoprotein B (Apo B),
total cholesterol (TC), HDL-C, VLDL-TG, and high-
sensitivity C-reactive protein (hsCRP) levels compared
with placebo [10]. IPE was generally well tolerated, with
a safety and tolerability profile similar to placebo. A
high percentage (73%) of the ANCHOR study patients
had diabetes mellitus. The objective of this post hoc
subgroup analysis was to evaluate the effects of IPE on
lipids, lipoproteins, and inflammatory biomarkers in the
patients with diabetes mellitus from the ANCHOR
study, with subanalysis by degree of glycemic control
(glycosylated hemoglobin A1c [A1c] above or below
the median).Methods
The cohort of patients with diabetes mellitus in the AN-
CHOR study was selected from the overall study popula-
tion. The methods used in ANCHOR have been published
previously [10]. Briefly, ANCHOR was a 12-week, phase 3,
multicenter, double-blind study including patients >18 years
of age at high risk for CVD (patients with clinical coronary
heart disease [CHD] or CHD risk equivalents [10-year
risk ≥20%]) as defined by the National Cholesterol Educa-
tion Program Adult Treatment Panel III (NCEP-ATP III)
guidelines [11]. The protocol was approved by the appro-
priate international review boards, and all patients under-
went the informed consent process prior to enrollment, as
evidenced by their written informed consent. Patients were
required to have been on stable statin therapy (atorvastatin,
rosuvastatin, or simvastatin with or without ezetimibe)
for ≥4 weeks at doses expected to produce “optimal” LDL-
C levels for high-risk patients (≥40 and <100 mg/dL) and to
continue the statin therapy throughout the study [10,11].
Patients were also required to maintain a stable diet and
level of exercise during the study [10].
Once enrolled, patients entered a 4- to 6-week lead-in
diet and lifestyle stabilization period. This lead-in period
also served as a medication washout period for any pa-
tients taking non-statin lipid-altering medications such
as niacin >200 mg daily, fibrates, fish oil, other products
containing OM-3 fatty acids, or other herbal products or
dietary supplements with potential lipid-altering effects at
the time of screening (6-week washout was required for
such patients). A 2- to 3-week lipid-qualifying period
followed the lead-in period, during which the specified cri-
teria of TG levels ≥200 and <500 mg/dL and LDL-C ≥40
and <100 mg/dL were required to be met. Patients who
met the lipid-qualifying criteria were randomized to IPE
4 g/day, 2 g/day, or matching placebo and entered the
double-blind, 12-week safety and efficacy period.
The presence of diabetes mellitus type 1 or 2 was con-
sidered to be one of the criteria for meeting the inclusion
requirement of the presence of CHD risk equivalents as
defined by the NCEP-ATP III guidelines [11]. Patients
who had A1c >9.5% or were being treated with antidiabetes
medication that had not been stable for ≥4 weeks at
screening were excluded from the ANCHOR study.
All of the diabetes subgroup analyses assessing the ef-
fects of IPE on lipids, lipoproteins, and biomarkers of in-
flammation were performed post hoc, with the exception
of TG level analysis, which was prespecified. The effects of
IPE on lipid, lipoprotein, and inflammation biomarker pa-
rameters were assessed in the intent-to-treat (ITT) popu-
lation, defined as all randomized patients who took ≥1
dose of any study drug, had a valid baseline laboratory
measurement, and had ≥1 valid post-randomization la-
boratory efficacy measurements of any type (ie, lipid, lipo-
protein, and inflammatory parameters). The efficacy
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with diabetes mellitus—overall median baseline A1c =
6.8%), patients with better-controlled diabetes mellitus
(percent A1c < overall median A1c), and patients with less-
controlled diabetes mellitus (percent A1c ≥ overall median
A1c). Subjects with missing baseline or week 12 measure-
ments, because of either missing laboratory samples or
unreportable values, were excluded from the analysis.
The primary efficacy variable was the median placebo-
adjusted percent change from baseline to week 12 in
fasting TG levels. Secondary efficacy variables included
LDL-C, non–HDL-C, VLDL-C, Lp-PLA2, and Apo B. Ex-
ploratory efficacy variables included TC, HDL-C, VLDL-
TG, hsCRP, oxidized LDL (Ox-LDL), and remnant-like
particle cholesterol (RLP-C). Exploratory diabetes parame-
ters included fasting plasma glucose (FPG), A1c, and
homeostasis model assessment-estimated insulin resistance
(HOMA-IR). Laboratory measurements were performed
by the central laboratory, Medpace Reference Laboratories
(Cincinnati, Ohio) as follows: Serum TG and cholesterol
concentrations were measured using enzymatic colorimet-
ric tests (Olympus AU2700 or AU5400 Analyzer, Olympus,
Center Valley, PA, USA) with calibration directly traceable
to the Centers for Disease Control reference proce-
dures. Serum HDL-C was isolated by precipitating
Apo B–containing lipoproteins (chylomicrons, VLDLs,
intermediate-density lipoproteins, and LDLs) with dex-
tran sulfate, and HDL-C was measured in the super-
natant [12]. Non–HDL-C was calculated by subtracting
HDL-C from TC. Serum LDL-C, VLDL-C, and VLDL-
TG were calculated from TC and TG and measured by
beta-quantification after preparative ultracentrifugation
[13]. Serum Apo B was measured using rate immu-
nonephelometry (Dade Behring BNII nephelometer,
Siemens Healthcare Diagnostics, Deerfield, IL, USA).
Immunonephelometry was used to measure serum hsCRP
(Dade Behring BNII nephelometer), serum RLP-C was
measured with an immunoseparation assay by Polymedco
(Cortlandt Manor, NY, USA) on the Daytona chemistry
analyzer (Randox, Crumlin, United Kingdom), and plasma
Ox-LDL concentrations were measured with solid-phase
2-site enzyme immunoassay (Mercodia, Winston Salem,
NC, USA). A1c, FPG, and insulin were measured with
high-performance liquid chromatography, photometry,
and an electrochemiluminescence immunoassay, respect-
ively. HOMA-IR was calculated as described by Matthews
et al. [14]. Berkeley Heart Laboratory (Burlingame, CA,
USA) measured Lp-PLA2 using the PLAC® enzyme-linked
immunosorbent assay (diaDexus, South San Francisco,
CA, USA).
Descriptive statistics and analyses were applied to the
diabetes subgroups, which were similar to those
performed on the overall ANCHOR study ITT popula-
tion [10]. Because significant departures from normalitywere observed for the overall ITT population, a non-
parametric analysis was performed for the subgroups,
and medians and quartiles were provided for each treat-
ment group. The median difference of each variable
(percent change from baseline) between each IPE treat-
ment group and the placebo group was evaluated with a
nonparametric test using the Hodges-Lehmann medians
of the differences between treatment groups and the
Wilcoxon rank-sum test. For exploratory efficacy param-
eters, it was prespecified that no adjustments were to be
made for multiplicity and that significance was defined
as a P ≤ 0.05.
Results
Among the patients randomized in the ANCHOR study,
513 (73%) were determined to have diabetes mellitus type
2. One patient had diabetes mellitus type 1. In the ITT
population (n = 501), there were 165, 171, and 165 patients
with diabetes mellitus assigned to the IPE 4 g/day, 2 g/day,
and placebo groups, respectively. The overall median base-
line A1c was 6.8% for the randomized population of pa-
tients with diabetes mellitus. In the subgroup of patients
with baseline A1c values below the overall median baseline
value (ie, better-controlled diabetes), the mean baseline A1c
was 6.2% (n = 253). In the subgroup of patients with A1c
values above the median baseline value (ie, less-controlled
diabetes), the mean baseline A1c was 7.6% (n = 261).
Baseline values for the efficacy end points are shown in
Table 1. In the IPE 4 g/day group, baseline values were
similar between all diabetes subgroups for all lipid, lipo-
protein, and inflammatory parameters with the exception
of hsCRP, which was numerically higher in the less-
controlled diabetes subgroup than in the better-controlled
diabetes subgroup. Similar results were observed in the
IPE 2 g/day and placebo groups. Significant placebo-
adjusted decreases in the end points of TG, non–HDL-C,
VLDL-C, Lp-PLA2, Apo B, TC, HDL-C, VLDL-TG, Ox-
LDL, and RLP-C were observed in patients treated with
IPE 4 g/day in all diabetes subgroups (Figure 1A; Table 1).
Although placebo-adjusted reductions in hsCRP were not
significant in the better-controlled diabetes group, signifi-
cant placebo-adjusted reductions were achieved in the total
and less-controlled diabetes subgroups (Figure 1A; Table 1).
Effects were numerically more pronounced in patients with
less-controlled diabetes for non–HDL-C, VLDL-C, Apo B,
TC, VLDL-TG, hsCRP, and Ox-LDL compared with pa-
tients with better-controlled diabetes (Figure 1A; Table 1).
In general, the magnitude of the reductions observed in pa-
tients receiving IPE 2 g/day was numerically lower than
that observed with IPE 4 g/day (Figure 1B; Table 1). Fur-
thermore, patients with less-controlled diabetes showed no
significant placebo-adjusted reductions for any parameter
following treatment with IPE 2 g/day. No statistically
significant placebo-adjusted increases in LDL-C were
Table 1 Change in efficacy parameters following IPE treatment in diabetes subgroups by median baseline A1c
Parameter All patients with
diabetes mellitus
A1c <6.8% A1c ≥6.8% All patients with
diabetes mellitus
A1c <6.8% A1c ≥6.8%
IPE dose (n = all patients,








change from baseline, %, p
TG (mg/dL)
4 g/day 262 217 262 228 268 203 -23.2 -21.0 -24.8
(n=165, 78, 87) (220-312) (179-267) (223-316) (186-290) (218-309) (166-261) <0.0001 <0.0001 <0.0001
2 g/day 254 244 264 238 250 248 -9.8 -15.1 -4.8
(n=171, 81, 90) (216-303) (199-315) (218-325) (196-307) (214-297) (203-318) <0.01 <0.01 0.39
Placebo 259 276 258 276 260 274
(n=165, 87, 78) (221-299) (214-367) (220-294) (210-343) (223-315) (216-379)
LDL-C (mg/dL)
4 g/day 81 83 85 83 79 83 -6.3 -6.6 -5.7
(n=165, 78, 87) (70-96) (69-98) (70-101) (69-96) (70-93) (69-100) 0.02 0.08 0.13
2 g/day 82 87 83 89 82 85 -3.8 -3.7 -4.7
(n=170, 80, 90) (73-97) (74-100) (76-97) (78-99) (69-96) (72-102) 0.15 0.33 0.25
Placebo 84 88 84 85 84 93
(n=164, 87, 77) (72-97) (74-105) (70-97) (75-102) (72-97) (72-108)
Non–HDL-C (mg/dL)
4 g/day 128 121 129 124 128 119 -14.4 -11.3 -18.0
(n=165, 78, 87) (111-146) (104-144) (111-146) (107-144) (111-146) (101-143) <0.0001 <0.01 <0.0001
2 g/day 125 135 128 135 124 136 -4.4 -4.6 -4.2
(n=171, 81, 90) (113-146) (117-158) (115-145) (119-154) (111-148) (113-162) 0.07 0.17 0.22
Placebo 128 136 128 136 130 140
(n=165, 87, 78) (113-147) (123-167) (114-142) (121-161) (112-154) (126-173)
VLDL-C (mg/dL)
4 g/day 44 37 45 41 43 35 -24.1 -14.3 -33.8
(n=165, 78, 87) (33-54) (29-50) (32-53) (31-52) (33-56) (28-47) <0.0001 0.01 <0.0001
2 g/day 42 42 42 44 42 42 -6.1 -3.8 -9.0
(n=170, 80, 90) (32-51) (33-58) (32-53) (30-60) (33-51) (34-55) 0.21 0.57 0.17
Placebo 42 49 42 45 43 53
(n=164, 87, 77) (35-56) (37-66) (35-56) (37-63) (36-54) (40-67)
Lp-PLA2 (ng/mL)
4 g/day 180 160 179 166 180 153 -19.1 -17.9 -20.3
(n=160, 75, 85) (160-212) (134-186) (161-213) (137-191) (153-211) (130-179) <0.0001 <0.0001 <0.0001
2 g/day 192 184 196 185 182 178 -7.5 -9.5 -5.7
(n=163, 78, 85) (164-219) (159-215) (169-237) (163-219) (161-212) (153-210) <0.001 <0.01 0.08
Placebo 184 197 189 200 181 188
(n=156, 85, 71) (159-219) (165-233) (166-221) (170-241) (142-216) (163-220)
Apo B (mg/dL)
4 g/day 91 89 91 90 91 88 -9.5 -6.1 -12.8
(n=160, 75, 85) (80-104) (79-105) (82-107) (80-107) (79-101) (78-103) <0.0001 0.02 <0.0001
2 g/day 91 95 91 96 91 95 -3.4 -2.1 -5.1
(n=166, 79, 87) (84-104) (86-107) (84-105) (87-106) (83-103) (85-112) 0.08 0.46 0.07
Placebo 93 98 93 96 93 103
(n=158, 86, 72) (82-105) (88-113) (82-104) (86-109) (82-106) (90-117)
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Table 1 Change in efficacy parameters following IPE treatment in diabetes subgroups by median baseline A1c
(Continued)
TC (mg/dL)
4 g/day 167 160 173 166 165 157 -12.7 -10.7 -15.1
(n=165, 78, 87) (147-188) (142-181) (150-189) (143-184) (145-187) (140-177) <0.0001 0.0001 <0.0001
2 g/day 166 176 170 177 164 175 -4.0 -4.1 -4.1
(n=171, 81, 90) (150-185) (154-198) (156-184) (162-196) (146-185) (151-201) 0.04 0.10 0.15
Placebo 167 181 167 181 168 184
(n=165, 87, 78) (151-190) (166-211) (154-189) (168-206) (147-191) (160-216)
HDL-C (mg/dL)
4 g/day 36 36 38 38 36 35 -5.0 -5.9 -4.3
(n=165, 78, 87) (31-43) (30-43) (32-45) (30-43) (30-42) (30-44) <0.01 0.02 0.05
2 g/day 39 40 40 41 39 39 -2.3 -1.6 -2.9
(n=171, 81, 90) (32-46) (33-45) (32-46) (34-47) (31-45) (32-45) 0.17 0.51 0.18
Placebo 38 39 41 40 37 38
(n=165, 87, 78) (32-45) (34-48) (33-47) (34-50) (32-42) (32-47)
VLDL-TG (mg/dL)
4 g/day 186 145 189 163 185 140 -28.9 -23.5 -34.1
(n=165, 78, 87) (147-245) (113-200) (147-238) (111-214) (140-249) (113-177) <0.0001 <0.001 <0.0001
2 g/day 181 168 186 172 177 163 -10.8 -10.9 -10.7
(n=170, 80, 90) (143-232) (136-236) (145-243) (136-239) (143-230) (136-236) 0.02 0.12 0.11
Placebo 186 202 176 196 197 209
(n=164, 87, 77) (145-238) (146-277) (142-224) (142-275) (146-243) (146-283)
Ox-LDL (U/L)
4 g/day 54 52 55 52 52 53 -16.1 -13.8 -17.4
(n=60, 29, 31) (46-60) (44-59) (49-58) (44-63) (44-66) (45-59) <0.0001 <0.01 <0.001
2 g/day 55 56 55 57 53 56 -8.9 -10.3 -8.2
(n=59, 24, 35) (48-66) (49-71) (49-59) (49-62) (48-69) (49-74) 0.03 0.07 0.15
Placebo 52 60 52 60 53 61
(n=64, 34, 30) (45-62) (51-70) (46-63) (51-66) (42-62) (47-73)
hsCRP (mg/L)
4 g/day 2.5 2.1 1.8 2.0 2.9 2.1 -21.5 -4.0 -34.6
(n=160, 75, 85) (1.3-4.1) (1.0-4.4) (1.1-3.6) (0.9-4.4) (1.4-4.9) (1.1-4.3) <0.01 0.74 <0.001
2 g/day 2.1 2.7 1.5 1.7 2.5 3.2 -8.2 -8.4 -8.7
(n=166, 79, 87) (1.0-4.6) (1.1-4.5) (0.9-3.1) (0.9-3.9) (1.3-5.8) (1.5-5.0) 0.26 0.41 0.41
Placebo 2.5 3.1 2.1 2.7 2.7 3.4
(n=158, 86, 72) (1.2-5.1) (1.3-6.0) (1.1-5.0) (1.2-6.1) (1.4-5.2) (1.4-5.9)
RLP-C (mg/dL)
4 g/day 13.0 10.0 14.0 11.5 12.5 9.0 -25.0 -26.7 -21.3
(n=60, 28, 32) (11.0-17.0) (8.0-13.6) (11.0-16.6) (8.0-14.5) (10.0-18.0) (8.0-11.5) <0.01 0.05 0.04
2 g/day 15.0 11.0 16.0 13.0 12.0 10.5 -16.6 -27.8 -3.0
(n=62, 32, 30) (11.0-18.0) (9.0-16.0) (13.0-18.5) (10.0-16.0) (10.0-18.0) (8.0-14.0) 0.06 0.02 0.84
Placebo 14.0 13.0 14.0 15.5 14.0 12.0
(n=61, 34, 27) (11.0-17.0) (9.0-20.0) (11.0-18.0) (11.0-22.0) (11.0-16.0) (9.0-16.0)
Data are presented as median (lower and upper quartile) for end point values.
Apo B = apolipoprotein B; HDL-C = high-density lipoprotein cholesterol; hsCRP = high-sensitivity C-reactive protein; IPE = icosapent ethyl; LDL-C = low-density
lipoprotein cholesterol; Lp-PLA2 = lipoprotein-associated phospholipase A2; non–HDL-C = non–high-density lipoprotein cholesterol; Ox-LDL = oxidized low-density
lipoprotein; RLP-C = remnant-like particle cholesterol; TC = total cholesterol; TG = triglyceride; VLDL-C = very-low-density lipoprotein cholesterol; VLDL-TG = very-
low-density lipoprotein triglycerides.
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ably, IPE 4 g/day significantly reduced placebo-adjusted
LDL-C by 6.3% in the population of all patients with
diabetes (Figure 1A; Table 1).
The mean baseline diabetes data in each diabetes sub-
group is shown in Table 2. Baseline values for FPG were
numerically higher in those with less-controlled diabetes
than those with better-controlled diabetes. In each of the
diabetes subgroups, no statistically significant placebo-
adjusted changes were observed in the diabetes end points
of FPG, A1c, HOMA-IR, or insulin following treatment
with IPE 4 g/day or 2 g/day (Table 2).
Discussion
In this subanalysis of the ANCHOR study, treatment with
IPE (a high-purity prescription form of EPA ethyl ester) at
a dose of 4 g/day was shown to significantly reduce TG
without raising LDL-C in a cohort of statin-treated pa-
tients with diabetes mellitus and residually high TG levels
(≥200 and <500 mg/dL) despite LDL-C control (≥40 and
<100 mg/dL). In the ANCHOR study, treatment with IPE
4 g/day resulted in numerically greater reductions in pa-
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Figure 1 Median placebo-adjusted percent change from baseline to w
baseline A1c. A) IPE 4 g/day; B) IPE 2 g/day. *P ≤ 0.0001;
†P < 0.001; ‡P < 0.
apolipoprotein B; HDL-C = high-density lipoprotein cholesterol; hsCRP = hi
density lipoprotein cholesterol; Lp-PLA2 = lipoprotein-associated phospholip
NS = not significant; Ox-LDL = oxidized low-density lipoprotein; RLP-C = re
VLDL-C = very-low-density lipoprotein cholesterol; VLDL-TG = very-low-denno diabetes mellitus [10]. In addition to improving TG
levels in patients with diabetes mellitus, this analysis found
that, compared with placebo, treatment with IPE 4 g/day
also significantly decreased placebo-adjusted non–HDL-C,
VLDL-C, Lp-PLA2, Apo B, TC, HDL-C, VLDL-TG, and
hsCRP. These results are consistent with those reported
for the overall ANCHOR population [10]. In this analysis,
Ox-LDL and RLP-C were also significantly decreased by
treatment with IPE 4 g/day. Of particular interest, the de-
creases in non–HDL-C, VLDL-C, Apo B, TC, VLDL-TG,
hsCRP, and Ox-LDL were numerically more pronounced
in patients who had less-controlled diabetes at baseline
compared with patients who had better-controlled dia-
betes at baseline.
The TG-lowering effects of OM-3 fatty acids are well
established, have been demonstrated in patients with dia-
betes mellitus [15,16], and are supported by this subanalysis
of the ANCHOR study. Significant reductions in TC, LDL-
C, and non–HDL-C have also recently been reported in a
small study of patients with diabetes mellitus-2 and
dyslipidemia following treatment with 1.8 g/day of purified
EPA [17]. However, in another small study of patients with
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eek 12 for efficacy end points in diabetes subgroups by median
01; §P ≤ 0.05. A1c = glycosylated hemoglobin A1c; Apo B =
gh-sensitivity C-reactive protein; IPE = icosapent ethyl; LDL-C = low-
ase A2; non–HDL-C = non-high-density lipoprotein cholesterol;
mnant-like particle cholesterol; TC = total cholesterol; TG = triglyceride;
sity lipoprotein triglycerides.
Table 2 Change in diabetes end points following IPE treatment in diabetes subgroups by median baseline A1c
Parameter All patients with
diabetes mellitus





≥6.8%IPE dose (n=all patients,







from baseline, %, p
FPG, mg/dL
4 g/day 143 154 122 133 161 172 3.7 2.7 4.0
(n=160, 75, 85) (38) (53) (23) (37) (39) (59) 0.16 0.38 0.35
2 g/day 146 150 123 127 167 171 0.1 -2.8 2.6
(n=165, 79, 86) (44) (47) (25) (26) (47) (51) 0.99 0.36 0.54
Placebo 140 145 124 130 158 163
(n=158, 86, 72) (35) (39) (25) (30) (37) (41)
A1c, %
4 g/day 6.9 7.2 6.2 6.5 7.6 7.9 1.4 1.3 1.7
(n=161, 76, 85) (0.9) (1.1) (0.3) (0.6) (0.7) (1.1) 0.14 0.27 0.29
2 g/day 7.0 7.2 6.2 6.3 7.8 8.0 0.1 -0.4 0.8
(n=167, 79, 88) (1.1) (1.2) (0.4) (0.5) (0.9) (1.1) 0.88 0.71 0.59
Placebo 6.8 7.0 6.2 6.4 7.5 7.7
(n=158, 86, 72) (0.9) (1.1) (0.4) (0.7) (0.7) (0.9)
Insulin, μIU/mL
4 g/day 20.6 18.5 20.0 19.3 21.2 17.7 -5.9 0.6 -13.4
(n=159, 76, 83) (16.0) (10.6) (12.1) (9.8) (19.0) (11.3) 0.43 0.95 0.26
2 g/day 18.9 19.1 16.8 17.4 21.1 20.7 -4.1 9.2 -17.8
(n=157, 79, 78) (11.6) (10.9) (9.3) (9.0) (13.2) (12.5) 0.59 0.32 0.14
Placebo 25.4 21.5 27.5 19.6 22.8 23.8
(n=156, 85, 71) (38.2) (18.9) (48.2) (13.9) (20.6) (23.5)
HOMA-IR
4 g/day 7.5 7.3 6.1 6.4 8.8 8.1 -1.4 3.0 -7.1
(n=158, 75, 83) (7.5) (6.2) (3.8) (3.7) (9.5) (7.7) 0.88 0.79 0.64
2 g/day 7.0 7.1 5.2 5.5 8.8 8.7 -8.8 6.0 -23.9
(n=157, 79, 78) (5.0) (4.8) (3.4) (3.1) (5.6) (5.6) 0.36 0.60 0.13
Placebo 9.6 7.9 9.7 6.4 9.4 9.6
(n=156, 85, 71) (19.0) (7.6) (24.1) (5.0) (9.9) (9.6)
Mean and standard deviation (SD) are reported for baseline and end-of-treatment values. Least-squares means are reported for the placebo-adjusted changes
from baseline.
A1c = glycosylated hemoglobin A1c; FPG = fasting plasma glucose; HOMA-IR = homeostasis model assessment-estimated insulin resistance; IPE = icosapent ethyl.
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but significant increases in TC and HDL-C but not in LDL-
C [18]. The dose was notably low at 1 g/day and there were
differences in tocopherol concentrations between the EPA
intervention and placebo formulations. As with the present
analysis, reductions in VLDL-C and VLDL-TG were also
reported in a systematic meta-analysis by Hartweg et al.
[15] of patients with diabetes mellitus-2 from studies
wherein most patients were treated with EPA plus DHA.
However, modest increases in LDL-C were noted in the
meta-analysis [15] while this subanalysis found no signifi-
cant change in LDL-C following treatment with IPE 2 g/
day and a statistically significant decrease of 6.3% in LDL-Cwith IPE 4 g/day compared with placebo in the population
of all patients with diabetes (P = 0.02). This ability of a pure
EPA product (such as IPE) to reduce LDL-C, in contrast
with pure DHA or DHA/EPA combinations, which tend to
raise LDL-C, is supported by 2 recent meta-analyses, which
found that while DHA raised LDL-C, EPA did not [19,20].
The potentially favorable decreases in TG, non–HDL-
C, VLDL-C, Apo B, hsCRP, Ox-LDL, and RLP-C levels
seen with IPE compared with placebo may be of clinical
importance because these parameters are more likely to
be abnormal in patients with diabetes mellitus (especially
when less controlled), and it is believed that increases in
lipid, lipoprotein, and inflammatory end points may
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Glycosylated hemoglobin has been shown to be signifi-
cantly and positively associated with elevated concentra-
tions of CRP [21]. In this study, baseline hsCRP was
numerically higher in patients with less-controlled dia-
betes mellitus than in those with better-controlled dia-
betes mellitus and thus may be indicative of greater
inflammation in patients with less-controlled diabetes
mellitus [22]. The reductions observed in RLP-C in the
present study may be clinically important because
remnant lipoproteins may be atherogenic [23,24]. The
finding that IPE does not increase (and may modestly
lower) LDL-C suggests a potential clinical benefit of IPE
in that it may not interfere with reaching or maintaining
LDL-C goal in patients with diabetes mellitus.
The clinical importance of a modest decrease of 5% in
HDL-C observed in this study with the 4 g/day dose com-
pared with placebo is unclear. This finding, however, is the
opposite of the modest increases in HDL-C often shown
with other OM-3 fatty acid treatments, especially those
with substantial DHA content, which is absent in IPE
[25,26]. Interestingly, an independent measure of HDL
concentration provided by nuclear magnetic resonance
(HDL particle concentration, HDL-P) has been reported
to decrease with both EPA-only [27] and combination
EPA/DHA OM-3 fatty acid preparations [28]. Further-
more, based on the results of 2 recent CVD outcomes tri-
als, AIM-HIGH and dal-OUTCOMES, the role of changes
in HDL-C levels as a reliable inverse predictor of changes
in CVD risk has been called into question [29,30].
No statistically significant changes in glycemic control
were observed following treatment with IPE 4 g/day or
2 g/day compared with placebo. This absence of observed
increases in glycemic measures may be of clinical import-
ance, since a prior study showed a statistically significant
increase in FPG following treatment with a prescription
formulation of EPA plus DHA [26]. In contrast, a recent
systematic review and meta-analysis found that consump-
tion of EPA and/or DHA did not alter the risk of the de-
velopment of diabetes mellitus [31].
A limitation of this study is the fact that all of the dia-
betes subgroup analyses were performed post hoc with the
exception of TG levels, which was prespecified. Further-
more, the effect of the reductions in lipid and inflammatory
parameters reported here and elsewhere on CVD risk with
OM-3 fatty acid treatment is not yet known, particularly in
patients with diabetes mellitus. However, the American
Diabetes Association recommends that OM-3 fatty acid
consumption in patients with diabetes be increased by con-
suming ≥2 servings of fish per week [32], and evidence has
begun to accrue, in subanalyses of OM-3 fatty acid levels
in several observational CVD outcomes studies in patients
with diabetes mellitus, that higher plasma OM-3 levels pre-
dict reduced CVD risk [33-39].Supplementation with 1 g/day OM-3 fatty acids was
found to reduce total mortality in patients with recent
myocardial infarction in the Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto miocardico-Prevenzione
trial (GISSI-Prevenzione) [33,34]. Approximately 15% of
the GISSI-Prevenzione patients had diabetes mellitus, and
a retrospective subgroup analysis found that the efficacy of
OM-3 fatty acid administration on total mortality was
similar in the absence and presence of diabetes mellitus
[35]. Secondary and post hoc exploratory analyses of pa-
tients with diabetes from the Alpha Omega Trial demon-
strated reductions in certain cardiovascular end points
with low-dose EPA plus DHA treatment [36,37]. In a
subanalysis of the Japan EPA Lipid Intervention Study
(JELIS), purified EPA was found to be very effective in re-
ducing the incidence of coronary artery disease in patients
with impaired glucose metabolism [39].
Furthermore, a recent review of clinical studies in
heart failure patients found that OM-3 fatty acids may
have preferential beneficial therapeutic effects in patients
with diabetes mellitus [38]. This is consistent with data
from a rodent model of type 2 diabetes mellitus, in
which myocardial content EPA and DHA was lower in
rats with type 2 diabetes mellitus and may therefore be a
factor associated with cardiac pathophysiology in type 2
diabetes mellitus [40].
In contrast to these positive results, recent results from
the Outcome Reduction with Initial Glargine Intervention
(ORIGIN) study found that treatment with EPA plus
DHA did not prevent death or any cardiovascular out-
comes in patients with increased risk of cardiovascular
events who had diabetes mellitus or who were at high risk
for diabetes mellitus [41]. A potential explanation for the
discrepancy in results between ORIGIN and JELIS is that
the dose of EPA, or EPA plus DHA, in JELIS was 1.8 g/
day, approximately twice that of ORIGIN (and indeed
most of the earlier studies).
The ongoing Reduction of Cardiovascular Events with
EPA-Intervention (REDUCE-IT; NCT1492361) study
will evaluate the effect of IPE 4 g/day on prevention of a
first major cardiovascular event in approximately 8000
patients with hypertriglyceridemia at high risk for car-
diovascular events, including a large cohort of patients
with diabetes mellitus. Results from REDUCE-IT prom-
ise to provide crucial information regarding the utility of
IPE for therapy in patients at risk for CVD, including pa-
tients with diabetes mellitus and associated dyslipidemia.
Conclusions
IPE 4 g/day significantly improved most major lipid and
lipoprotein parameters (including TG-rich remnant lipo-
proteins) and inflammatory parameters without worsen-
ing LDL-C or glycemic control in patients with diabetes
and mixed dyslipidemia. Many of these effects appeared
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suggesting that IPE may be especially beneficial in pa-
tients with diabetes when optimal glycemic control has
not been or cannot be achieved.
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